Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments.
The minimal inhibitory concentrations for 90% of strains (MIC90) of ofloxacin against Mycobacterium tuberculosis and Mycobacterium xenopi was 2 mg/l. This was three dilutions lower than that of pefloxacin and was well within the range of drug concentrations achievable in man. The antituberculosis activities of both quinolones were independent of resistance of the strains to other antimycobacterial agents. Mycobacterium avium-intracellulare was resistant to both compounds with MIC90s greater than 16 mg/l. The maximum serum levels (Cmax) of both compounds increased proportionally with increasing dose size. The terminal elimination half-life (T1/2) of pefloxacin was longer than that of ofloxacin, but the T1/2 of both compounds in mice were much shorter than in man. The area under the concentration curve (AUC) of pefloxacin was double than that of ofloxacin. In the mouse, pefloxacin at doses up to 150 mg/kg daily was inactive against M. tuberculosis infection: in terms of survival rate the minimal effective dose of ofloxacin against M. tuberculosis infection was 150 mg/kg daily when given by gavage or by incorporation into the mouse diet at a concentration of 0.1%, but in terms of cfu counts, ofloxacin 150 mg/kg daily only displayed a moderate degree of activity similar to ethambutol 100 mg/kg daily. The therapeutic effects of ofloxacin against M. tuberculosis infection were dose-related: 300 mg/kg daily by gavage or 0.4% in mouse diet displayed much better therapeutic effects than lower dosages. Since the AUC in mice treated with ofloxacin 150 mg/kg daily is close to that in man treated with a clinically tolerated dose--600 mg daily--such a dosage may be only moderately effective against human tuberculosis.
Truffot-Pernot
C
C
Service de Bacteriologie et Virologie, Faculté de Médecine Pitié-Salpêtrière, Paris, France.
Ji
B
B
Grosset
J
J
D000818:Animals; D005260:Female; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D009170:Nontuberculous Mycobacteria / Q000187:drug effects; D015242:Ofloxacin / Q000097:blood / Q000627:therapeutic use*; D015366:Pefloxacin / Q000097:blood / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy* / Q000401:mortality
D015366:Pefloxacin; D015242:Ofloxacin